<DOC>
	<DOCNO>NCT00354445</DOCNO>
	<brief_summary>The purpose study explore safety efficacy Macugen give maintenance therapy patient initial success another AMD treatment . Patients must 1 , 3 prior treatment Neovascular AMD .</brief_summary>
	<brief_title>A Clinical Trial Explore Safety Efficacy Injections Macugen When Given Every 6 Weeks Subjects With AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Subfoveal CNV secondary AMD At least 1 3 prior treatment AMD Subfoveal scar subfoveal atrophy Significant medium opacity , include cataract , might interfere visual acuity</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Age-Related Macular Degeneration ( AMD )</keyword>
	<keyword>pegaptanib sodium</keyword>
	<keyword>subfoveal CNV</keyword>
	<keyword>macugen</keyword>
</DOC>